Sarasini A, Baldanti F, Furione M, Percivalle E, Brerra R, Barbi M, Gerna G
Viral Diagnostic Service, University of Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Italy.
J Med Virol. 1995 Nov;47(3):237-44. doi: 10.1002/jmv.1890470309.
Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance. Peripheral blood leukocytes (PBL), the relevant conventional viral isolates, and plaque-purified strains from all four patients were examined by antiviral drug susceptibility testing by an immediate-early antigen plaque reduction assay and by restriction fragment length polymorphism (RFLP) analysis using polymerase chain reaction (PCR)-amplified multiple genome regions and endonucleases. All four HCMV strains had a high level of resistance to both ganciclovir and foscarnet. A single HCMV strain was shown to be responsible for the dual resistance in each patient. HCMV strain identity and uniqueness were shown for each of the four patients in blood samples, viral isolates, and plaque-purified strains. In addition, in two patients the same single HCMV strain shifted progressively from drug sensitivity to ganciclovir and then to ganciclovir-foscarnet resistance. These findings document that resistance to both ganciclovir and foscarnet of HCMV strains recovered from blood of AIDS patients represents an emerging problem. Although it is known that multiple HCMV strains may cocirculate in the blood of AIDS patients, single strains appear to be responsible for the dual resistance. Molecular mechanisms responsible for the double resistance of the four reported strains are under study.
对4例接受更昔洛韦和膦甲酸钠联合治疗但临床对抗病毒治疗无反应的不同艾滋病患者的4株人巨细胞病毒(HCMV)分离株进行了研究,以验证对这两种药物的双重耐药性是否发生,并确定单一或多个HCMV毒株是否可能导致双重耐药性。通过即时早期抗原蚀斑减少试验进行抗病毒药物敏感性测试,并使用聚合酶链反应(PCR)扩增多个基因组区域和核酸内切酶进行限制性片段长度多态性(RFLP)分析,对所有4例患者的外周血白细胞(PBL)、相关的传统病毒分离株和蚀斑纯化毒株进行了检测。所有4株HCMV毒株对更昔洛韦和膦甲酸钠均具有高度耐药性。结果表明,每例患者的双重耐药性均由单一HCMV毒株引起。在血液样本、病毒分离株和蚀斑纯化毒株中,显示了4例患者各自的HCMV毒株的同一性和独特性。此外,在2例患者中,同一单一HCMV毒株逐渐从对更昔洛韦敏感转变为对更昔洛韦耐药,然后转变为对更昔洛韦-膦甲酸钠耐药。这些发现证明,从艾滋病患者血液中分离出的HCMV毒株对更昔洛韦和膦甲酸钠的耐药性是一个新出现的问题。虽然已知多种HCMV毒株可能在艾滋病患者血液中共同循环,但单一毒株似乎是双重耐药性的原因。导致所报道的4株毒株双重耐药性的分子机制正在研究中。